Zoetis (ZTS) Income towards Parent Company (2012 - 2026)
Zoetis (ZTS) reported Income towards Parent Company of $601.0 million for Q1 2026, little changed year-over-year from $602.0 million in Q1 2025, and little changed quarter-over-quarter from $603.0 million in Q4 2025.
Zoetis (ZTS) Income towards Parent Company (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Income towards Parent Company data on file, last reported at $601.0 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $601.0 million, changed 0.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 5.76% YoY), and the FY2025 annual result was $2.7 billion, up 7.09% from the prior year.
- Income towards Parent Company was little changed at $601.0 million in Q1 2026 per ZTS's latest filing, from $603.0 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $721.0 million in Q3 2025 and troughed at $460.0 million in Q4 2022.
- A 5-year average of $599.5 million and a median of $599.0 million in 2024 frame the typical range for Income towards Parent Company.
- On a YoY basis, Income towards Parent Company climbed as much as 26.65% in 2023 and fell as far as 7.24% in 2023.
- A 5-year view of Income towards Parent Company shows it stood at $460.0 million in 2022, then gained by 13.7% to $523.0 million in 2023, then grew by 11.09% to $581.0 million in 2024, then gained by 3.79% to $603.0 million in 2025, then dropped by 0.33% to $601.0 million in 2026.
- Business Quant data shows ZTS's Income towards Parent Company at $601.0 million in Q1 2026, $603.0 million in Q4 2025, and $721.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 601.00 Mn |
| Dec 31, 2025 | 603.00 Mn |
| Sep 30, 2025 | 721.00 Mn |
| Jun 30, 2025 | 718.00 Mn |
| Mar 31, 2025 | 602.00 Mn |
| Dec 31, 2024 | 581.00 Mn |
| Sep 30, 2024 | 692.00 Mn |
| Jun 30, 2024 | 624.00 Mn |
| Mar 31, 2024 | 599.00 Mn |
| Dec 31, 2023 | 523.00 Mn |
| Sep 30, 2023 | 596.00 Mn |
| Jun 30, 2023 | 670.00 Mn |
| Mar 31, 2023 | 551.00 Mn |
| Dec 31, 2022 | 460.00 Mn |
| Sep 30, 2022 | 528.00 Mn |
| Jun 30, 2022 | 529.00 Mn |
| Mar 31, 2022 | 594.00 Mn |
| Dec 31, 2021 | 413.00 Mn |
| Sep 30, 2021 | 552.00 Mn |
| Jun 30, 2021 | 511.00 Mn |